BioVersys AG Income Statement

Financials in millions CHF. Fiscal year is January - December.

Millions CHF. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Other Revenue	1.31	1.21	1.14
Revenue	1.31	1.21	1.14
Revenue Growth (YoY)	-	6.50%	-
Gross Profit	1.31	1.21	1.14
Selling, General & Admin	6.41	7	4.02
Research & Development	12.61	12.95	14.83
Operating Expenses	19.02	19.94	18.84
Operating Income	-17.71	-18.73	-17.7
Interest Expense	-1.02	-1.03	-0.7
Interest & Investment Income	0.26	0.5	0.48
Currency Exchange Gain (Loss)	-0.04	0.13	-0.16
Other Non Operating Income (Expenses)	-0.84	0.42	-0.22
Pretax Income	-19.36	-18.72	-18.3
Net Income	-19.36	-18.72	-18.3
Net Income to Common	-19.36	-18.72	-18.3
Shares Outstanding (Basic)	4	3	3
Shares Outstanding (Diluted)	4	3	3
Shares Change (YoY)	-	11.60%	-
EPS (Basic)	-4.34	-5.62	-6.13
EPS (Diluted)	-4.34	-5.62	-6.13
Free Cash Flow	-16.71	-15.61	-11.7
Free Cash Flow Per Share	-3.75	-4.68	-3.92
Gross Margin	100.00%	100.00%	100.00%
Operating Margin	-1353.25%	-1544.11%	-1554.17%
Profit Margin	-1478.84%	-1543.20%	-1606.76%
Free Cash Flow Margin	-1276.39%	-1287.06%	-1027.57%
EBITDA	-17.65	-18.67	-17.65
D&A For EBITDA	0.06	0.06	0.06
EBIT	-17.71	-18.73	-17.7
Revenue as Reported	1.31	1.21	1.14

Source: S&P Global Market Intelligence. Standard template. Financial Sources.